CoChat

Mitigating Age-Related Immune Dysfunction Heightens the Efficacy of Tumor Immunotherapy in Aged Mice

Open access
Hurez, Vincent, Daniel, Benjamin J., Sun, Lishi, Liu, Ai-Jie, Ludwig, Sara M., Kious, Mark J., Thibodeaux, Suzanne R., Pandeswara, Srilakshmi, Murthy, Kruthi, Livi, Carolina B., Wall, Shawna, Brumlik, Michael J., Shin, Tahiro, Zhang, Bin, Curiel, Tyler J. · 2012 · Cancer Research
Cited by 109

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Although cancer tends to affect the elderly, most preclinical studies are carried out in young subjects. In this study, we developed a melanoma-specific cancer immunotherapy that shows efficacy in aged but not young hosts by mitigating age-specific tumor-associated immune dysfunction. Both young and aged CD4+CD25hi regulatory T cells (Treg) exhibited equivalent in vitro T-cell suppression and tumor-associated augmentation in numbers. However, denileukin diftitox (DT)-mediated Treg depletion improved tumor-specific immunity and was clinically effective only in young mice. DT-mediated Treg depletion significantly increased myeloid-derived suppressor cell (MDSC) numbers in aged but not young mice, and MDSC depletion improved tumor-specific immunity and reduced tumor growth in aged mice. Combining Treg depletion with anti–Gr-1 antibody was immunologically and clinically more efficacious than anti–Gr-1 antibody alone in aged B16-bearing mice, similar to Treg depletion alone in young mice. In contrast, DT increased MDSCs in young and aged mice following MC-38 tumor challenge, although effects were greater in aged mice. Anti–Gr-1 boosted DT effects in young but not aged mice. Aged antitumor immune effector cells are therefore competent to combat tumor when underlying tumor-associated immune dysfunction is appropriately mitigated, but this dysfunction varies with tumor, thus also varying responses to immunotherapy. By tailoring immunotherapy to account for age-related tumor-associated immune dysfunctions, cancer immunotherapy for aged patients with specific tumors can be remarkably improved. Cancer Res; 72(8); 2089–99. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-3019

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 109

Metadata

Authors
Hurez, V., Daniel, B. J., Sun, L., Liu, A.-J., Ludwig, S. M., Kious, M. J., Thibodeaux, S. R., Pandeswara, S., Murthy, K., Livi, C. B., Wall, S., Brumlik, M. J., Shin, T., Zhang, B., & Curiel, T. J.
Venue
Cancer Research
Published
2012-04-15
Volume
72
Issue
8
Pages
2089-2099
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2170682645
Cited by
109
References
3
FWCI
2.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mitigating Age-Related Immune Dysfunction Heightens the Efficacy of Tumor Immunotherapy in Aged Mice. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-3019
The paper
Hurez, V., Daniel, B. J., Sun, L., Liu, A.-J., Ludwig, S. M., Kious, M. J., Thibodeaux, S. R., Pandeswara, S., Murthy, K., Livi, C. B., Wall, S., Brumlik, M. J., Shin, T., Zhang, B., & Curiel, T. J. (2012). Mitigating Age-Related Immune Dysfunction Heightens the Efficacy of Tumor Immunotherapy in Aged Mice. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-3019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.